Production report for March 2024

Written by Customer Service on April 15, 2024. Posted in Public Companies.

Oslo, 15 April 2024 Feb 2024 March 2024 Operated Boepd (1) Bopd (2) Boepd (1) Bopd (2) Colombia 728 526 699 492 Argentina 1,419 323 1,584 270 Total operated 2,147 850 2,283 762 Total equity 1,091 480 1,145 436 (1) Barrels of oil equivalents per day (includes liquid and gas)(2) Barrels of oil per day (represents only liquids) [boepd]: barrels of oil equivalents per day (includes liquid and gas)[Operated]: 100% field production operated by Interoil[Equity] : Interoil’s share production net of royalties. Comments Interoil’s total daily average operated production in March increased by 135 boepd compared with February. The increase is mainly coming from fields in Argentina whereas Colombia reduced its operated production. In Argentina, the operated production increased by 165 boepd, as the arrival of some...

BRP and its Principal Shareholder Announce Bought Deal Secondary Offering

Written by Customer Service on April 15, 2024. Posted in Public Companies.

VALCOURT, Quebec, April 15, 2024 (GLOBE NEWSWIRE) — BRP Inc. (TSX:DOO; NASDAQ:DOOO) (“BRP” or the “Company”) announced today that Bain Capital Integral Investors II, L.P. (“Bain” or the “Selling Shareholder”), and the Company have entered into an agreement with BMO Capital Markets to complete a secondary offering on a bought deal basis (the “Offering”). Under the agreement, BMO Capital Markets has agreed to purchase 1,500,000 subordinate voting shares of the Company (the “Subordinate Voting Shares”) at a price to the public of C$92.90 per subordinate voting share. In connection with the Offering, the Company will file a preliminary prospectus supplement to its short form base shelf prospectus dated February 23, 2023. The preliminary prospectus supplement will be filed with the securities regulatory authorities...

Axalta Named a 2023 General Motors Supplier of the Year

Written by Customer Service on April 15, 2024. Posted in Public Companies.

Axalta recognized by General Motors as a top global supplier of 2023 Axalta’s Dan Naugle (VP, Mobility Americas), Rob Schnell (VP, Global Product Strategy and Commercial Operations) and Dagan Brush (Global Business Director) along with a GM representative at General Motors’ annual Supplier of the Year recognition event in Miami. PHILADELPHIA, April 15, 2024 (GLOBE NEWSWIRE) — Axalta Coating Systems (NYSE: AXTA), a leading global coatings company, was recognized by General Motors as a top global supplier of 2023 during its annual Supplier of the Year recognition event last week in Miami. In total, 86 suppliers were recognized with a Supplier of the Year award. “We are proud to be recognized by General Motors again as a 2023 Supplier of the Year,” said Hadi Awada, President, Global Mobility Coatings, Axalta. “Through...

FEMSA Schedules Conference Call to Discuss First Quarter Financial Results

Written by Customer Service on April 15, 2024. Posted in Public Companies.

MONTERREY, Mexico, April 15, 2024 (GLOBE NEWSWIRE) — Fomento Económico Mexicano, S.A.B. de C.V. (“FEMSA” or the “Company”) (NYSE: FMX; BMV: FEMSAUBD, FEMSAUB) is pleased to invite you to participate in its First Quarter Conference Call that will be held on: Friday, April 26, 202411:00 AM Eastern Time(9:00 AM Mexico City Time) To participate in the conference call please dial:Toll Free US: (866) 580 3963International: +1 (786) 697 3501Conference ID: FEMSA The quarterly results will be released on April 26 before markets open. The conference call will be webcast live through streaming audio. For details, please visit http://ir.femsa.com. If you are unable to participate live, the conference call replay will be available on http://ir.femsa.com/results.cfm. About FEMSAFEMSA is a company that creates economic and social value through...

BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement

Written by Customer Service on April 15, 2024. Posted in Public Companies.

MISSISSAUGA, Ontario, April 15, 2024 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSyent Pharma”), has extended its Exclusive License and Distribution Agreement with its European partner for the RepaGyn® and Proktis-M® products, extending BioSyent Pharma’s exclusive Canadian rights to these products until 2032. “RepaGyn® and Proktis-M® have been part of our product portfolio since we first launched these products in Canada in 2014,” commented René Goehrum, President and CEO of BioSyent. “We are pleased to continue to offer these trusted products to Canadian patients over the long-term and we look forward to their continued growth.” About RepaGyn® RepaGyn® is an innovative vaginal suppository recommended for relieving...

RYVYL Inc. Announces Launch of Proposed Underwritten Public Offering

Written by Customer Service on April 15, 2024. Posted in Public Companies.

San Diego, CA, April 15, 2024 (GLOBE NEWSWIRE) — RYVYL Inc. (NASDAQ: RVYL) (“RYVYL” or the “Company”), a leading innovator of payment transaction solutions leveraging proprietary blockchain ledger and electronic token technology for the diverse international markets, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares of common stock are being offered by RYVYL. In addition, RYVYL intends to grant the underwriter in the offering a 45-day option to purchase up to an additional 15% of the number of shares of common stock offered in the offering at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may...

PrimeEnergy Resources Corporation (PNRG) Announces Yearend Production and Financial Results

Written by Customer Service on April 15, 2024. Posted in Earnings Releases And Operating Results.

HOUSTON, April 15, 2024 (GLOBE NEWSWIRE) — PrimeEnergy Resources Corporation (PNRG) Announces Yearend Production and Financial Results: Years endedDecember 31, 2023 2022 Increase Increase Oil production (barrels) 1,144,000 939,000 205,000 21.83 % Natural gas production (Mcf) 4,127,000 3,325,000 802,000 24.12 % Natural gas liquids production (barrels) 606,000 417,000 189,000 45.32 % Proved reserves at December 31, 2023, were 12,011,000 barrels of oil, 8,832,000 barrels of natural gas liquids, and 49,219,000 Mcf of natural gas; or 29,046,000 barrels of oil equivalents. Year Ended December 31, 2023 2022 (Decrease) Revenues (In 000’s) $ 123,125 $ 137,096 $ (13,971 ) Net Income (In 000’s) $ 28,103 $ 48,664 $ (20,561 ) Earnings...

Gildan Activewear CEO Vince Tyra provides key focus strategic priorities

Written by Customer Service on April 15, 2024. Posted in Public Companies.

Company Reconfirms 2024 Full Year GuidanceAnnounces Preliminary Q1 2024 RevenueCompany to Host Investor Day in Fall 2024 MONTREAL, April 15, 2024 (GLOBE NEWSWIRE) — Gildan Activewear Inc. (GIL; TSX and NYSE) today announced that its President and CEO, Vince Tyra has unveiled his key focus strategic priorities. Concurrently, the Company also reconfirmed its 2024 full year guidance and announced preliminary Q1 revenue. Furthermore, the Company intends to hold an Investor Day in the Fall of 2024 to provide a comprehensive strategic plan. Reflecting on his first 90 days, Vince Tyra said, “I’m excited to be leading Gildan at this pivotal time. Having completed 90 days at the helm of Gildan, I wanted to share with you my key focus strategic priorities and articulate how we can leverage our strengths and accelerate value creation for...

Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million

Written by Customer Service on April 15, 2024. Posted in Public Companies.

ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that it has closed its previously announced private placement with Syntone Ventures, LLC, an existing stockholder, for upfront gross proceeds of approximately $5.0 million from the issuance and sale of shares of the Company’s common stock and accompanying warrants, before deducting offering expenses. In addition, Outlook Therapeutics has the potential to receive additional gross proceeds of up to $8 million upon the full cash exercise of the warrants issued in the private placement, before deducting offering expenses. About the Private Placement Pursuant...

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

Written by Customer Service on April 15, 2024. Posted in Public Companies.

Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations Additionally, the company initiated an extension cohort to evaluate ORIC-114 for the treatment of patients with first-line, treatment-naïve EGFR exon 20 NSCLC Expect to report updated Phase 1b data in the first half of 2025 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the completion of the dose escalation portion of the Phase 1b trial of ORIC-114 in patients with advanced solid tumors with EGFR and HER2 exon 20 alterations or HER2 amplifications. Based upon these data,...

Day: April 15, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice